Top

Infection

Published in:

01-02-2013 | Clinical and Epidemiological Study

Fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in Korean community and hospital settings

Authors: Y. J. Ko, H.-W. Moon, M. Hur, C.-M. Park, S. E. Cho, Y.-M. Yun

Published in: Infection | Issue 1/2013

Abstract

Purpose

The assessment and early recognition of risk factors for infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) are important for infection control and proper treatment. The aim of the present study was to investigate the prevalence of fecal carriage of ESBL-E in healthy individuals and hospitalized high-risk patients in Korea and to compare the characteristics of ESBL-E in these two groups.

Methods

A total of 384 samples from 290 healthy individuals and 94 high-risk patients were collected. The screening of ESBL-E was performed using a commercial chromogenic medium. Bacterial identification and antibiotic susceptibility testing were performed using the Vitek 2 system.

Results

The prevalence of ESBL-E carriage was 20.3 % in healthy individuals and 42.5 % in high-risk patients. Escherichia coli comprised a large majority (96.6 %) of the isolates from healthy individuals, but Klebsiella pneumoniae was more commonly detected (45.0 %) in high-risk patients than in healthy individuals. K. pneumoniae isolates exhibited significantly higher resistance to ceftazidime, ampicillin, and carbapenem, and E. coli exhibited higher resistance to cefotaxime. E. coli from high-risk patients exhibited significantly higher resistance to levofloxacin and cefepime than that from healthy individuals.

Conclusions

We demonstrated the high prevalence of ESBL-E carriage in Korea and clarified the characteristics of ESBL-E carriage in healthy individuals and high-risk patients. The distribution and antibiotic susceptibility of colonizing ESBL-E were different between the group of healthy individuals and the high-risk patients. Active surveillance of ESBL-E carriage is suggested for infection control, and the use of chromogenic agar appears to be an efficient method.

Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159–66. doi:10.1016/S1473-3099(08)70041-0.PubMedCrossRef

Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2006;50:1257–62. doi:10.1128/AAC.50.4.1257-1262.2006.PubMedCrossRef

Lucet JC, Decré D, Fichelle A, Joly-Guillou ML, Pernet M, Deblangy C, et al. Control of a prolonged outbreak of extended-spectrum beta-lactamase-producing Enterobacteriaceae in a university hospital. Clin Infect Dis. 1999;29:1411–8. doi:10.1086/313511.PubMedCrossRef

Reddy P, Malczynski M, Obias A, Reiner S, Jin N, Huang J, et al. Screening for extended-spectrum beta-lactamase-producing Enterobacteriaceae among high-risk patients and rates of subsequent bacteremia. Clin Infect Dis. 2007;45:846–52. doi:10.1086/521260.PubMedCrossRef

Troché G, Joly LM, Guibert M, Zazzo JF. Detection and treatment of antibiotic-resistant bacterial carriage in a surgical intensive care unit: a 6-year prospective survey. Infect Control Hosp Epidemiol. 2005;26:161–5. doi:10.1086/502521.PubMedCrossRef

De Champs C, Sauvant MP, Chanal C, Sirot D, Gazuy N, Malhuret R, et al. Prospective survey of colonization and infection caused by expanded-spectrum-beta-lactamase-producing members of the family Enterobacteriaceae in an intensive care unit. J Clin Microbiol. 1989;27:2887–90.PubMed

Holländer R, Ebke M, Barck H, von Pritzbuer E. Asymptomatic carriage of Klebsiella pneumoniae producing extended-spectrum beta-lactamase by patients in a neurological early rehabilitation unit: management of an outbreak. J Hosp Infect. 2001;48:207–13. doi:10.1053/jhin.2001.0997.PubMedCrossRef

Ko KS, Lee MY, Song JH, Lee H, Jung DS, Jung SI, et al. Prevalence and characterization of extended-spectrum beta-lactamase-producing Enterobacteriaceae isolated in Korean hospitals. Diagn Microbiol Infect Dis. 2008;61:453–9. doi:10.1016/j.diagmicrobio.2008.03.005.PubMedCrossRef

Song W, Lee H, Lee K, Jeong SH, Bae IK, Kim JS, et al. CTX-M-14 and CTX-M-15 enzymes are the dominant type of extended-spectrum beta-lactamase in clinical isolates of Escherichia coli from Korea. J Med Microbiol. 2009;58:261–6. doi:10.1099/jmm.0.004507-0.PubMedCrossRef

10.

Clinical and Laboratory Standards Institute (CLSI). Performances Standards for Antimicrobial Susceptibility Testing; 21st Informational Supplement M100–S21. Wayne, PA: CLSI; 2011.

11.

Valverde A, Coque TM, Sánchez-Moreno MP, Rollán A, Baquero F, Cantón R. Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol. 2004;42:4769–75. doi:10.1128/JCM.42.10.4769-4775.2004.PubMedCrossRef

12.

Glupczynski Y, Berhin C, Bauraing C, Bogaerts P. Evaluation of a new selective chromogenic agar medium for detection of extended-spectrum beta-lactamase-producing Enterobacteriaceae. J Clin Microbiol. 2007;45:501–5. doi:10.1128/JCM.02221-06.PubMedCrossRef

13.

Meyer E, Serr A, Schneider C, Utzolino S, Kern WV, Scholz R, et al. Should we screen patients for extended-spectrum beta-lactamase-producing Enterobacteriaceae in intensive care units? Infect Control Hosp Epidemiol. 2009;30:103–5. doi:10.1086/592702.PubMedCrossRef

14.

Huang TD, Bogaerts P, Berhin C, Guisset A, Glupczynski Y. Evaluation of Brilliance ESBL agar, a novel chromogenic medium for detection of extended-spectrum-beta- lactamase-producing Enterobacteriaceae. J Clin Microbiol. 2010;48:2091–6. doi:10.1128/JCM.02342-09.PubMedCrossRef

15.

Luvsansharav UO, Hirai I, Niki M, Nakata A, Yoshinaga A, Moriyama T, et al. Prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae among healthy adult people in Japan. J Infect Chemother. 2011;17:722–5. doi:10.1007/s10156-011-0225-2.PubMedCrossRef

16.

Tian SF, Chen BY, Chu YZ, Wang S. Prevalence of rectal carriage of extended-spectrum beta-lactamase-producing Escherichia coli among elderly people in community settings in China. Can J Microbiol. 2008;54:781–5. doi:10.1139/w08-059.PubMedCrossRef

17.

Sasaki T, Hirai I, Niki M, Nakamura T, Komalamisra C, Maipanich W, et al. High prevalence of CTX-M beta-lactamase-producing Enterobacteriaceae in stool specimens obtained from healthy individuals in Thailand. J Antimicrob Chemother. 2010;65:666–8. doi:10.1093/jac/dkq008.PubMedCrossRef

18.

Lee SG, Jeong SH, Lee H, Kim CK, Lee Y, Koh E, et al. Spread of CTX-M-type extended-spectrum beta-lactamases among bloodstream isolates of Escherichia coli and Klebsiella pneumoniae from a Korean hospital. Diagn Microbiol Infect Dis. 2009;63:76–80. doi:10.1016/j.diagmicrobio.2008.09.002.PubMedCrossRef

19.

Bae IK, Lee YN, Jeong SH, Lee K, Lee H, Kwak HS, et al. High prevalence of SHV-12 and the emergence of CTX-M-12 in clinical isolates of Klebsiella pneumoniae from Korea. Int J Antimicrob Agents. 2007;29:362–4. doi:10.1016/j.ijantimicag.2006.10.009.PubMedCrossRef

20.

Rodríguez-Baño J, Navarro MD, Romero L, Martínez-Martínez L, Muniain MA, Perea EJ, et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol. 2004;42:1089–94.PubMedCrossRef

Title: Fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in Korean community and hospital settings
Authors: Y. J. Ko
H.-W. Moon
M. Hur
C.-M. Park
S. E. Cho
Y.-M. Yun
Publication date: 01-02-2013
Publisher: Springer-Verlag
Published in: Infection / Issue 1/2013
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI: https://doi.org/10.1007/s15010-012-0272-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

De-escalation of antimicrobial therapy for bacteraemia due to difficult-to-treat Gram-negative bacilli

Changing trend in bile microbiology and antibiotic susceptibilities: over 12 years of experience

Detection of herpes viruses in the cerebrospinal fluid of adults with suspected viral meningitis in Malawi

Community-acquired left-sided Pseudomonas aeruginosa endocarditis in a patient without intravenous drug use

Validation of a multiplex reverse transcriptase PCR ELISA for the detection of 19 respiratory tract pathogens

Could anti-HCV treatment prevent recurrence of hepatocellular carcinoma in HIV-infected patients? Two case reports

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials